Pharmaceuticals

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-11-14 21:30 1979

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 3697

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based...

2023-11-14 06:33 2412

Rx-360 Releases Two New Publications in Support of the Pharmaceutical Industry and Patient Safety

PHILADELPHIA, Nov. 14, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium membership led by key members of the Supplier Quality Working Group have released two new papers this week to help drive best practices in pharmaceutical supply chain integrity and patient safety. The t...

2023-11-14 03:00 3175

SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus ...

2023-11-14 02:00 4508

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical c...

2023-11-13 20:20 2272

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to la...

2023-11-13 18:31 2113

Fundiin partners with Pharmacity to launch BNPL at a thousand drugstores in Vietnam

Fundiin and Pharmacity have forged the first-ever Buy Now Pay Later (BNPL) partnership in the pharmacy retail sector, with Fundiin being the most popular BNPL provider inVietnam and Pharmacity emerging as the regional leading drugstore chain. HO CHI MINH CITY, Vietnam, Nov. 13, 2023 /PRNewswire/...

2023-11-13 14:58 4614

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...

2023-11-13 08:10 3916

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center inSouth Korea. Colorectal cancer (CRC) is o...

2023-11-13 08:00 4704

Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability

Company attributes B+ rating to progress related to its Human Rights Management Declaration, eco-friendly shipping box and the establishment of an internal ESG Committee SEOUL, South Korea, Nov. 10, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total so...

2023-11-10 20:00 4936

Shaping Global Policy: IFPA's Psoriatic Disease Response Index in the Western Pacific

STOCKHOLM, Nov. 10, 2023 /PRNewswire/ -- Psoriatic disease, recognized as a serious noncommunicable disease by the World Health Organization (WHO), impacts millions worldwide. A pioneering advocacy tool, the Psoriatic Disease Response Index, has emerged to facilitate a vital policy discussion, dr...

2023-11-10 19:18 5105

H2U Secures Strategic Investment from InnoTherapy as Recognition from Seoul Clinical Laboratories (SCL)

H2U platform enters the South Korean healthcare sector, driving AI-powered data analytics to expand their digital health offerings TAIPEI, Nov. 10, 2023 /PRNewswire/ -- H2U, Taiwan's premier digital health brand, proudly announced another successful round of funding this year after receiving rec...

2023-11-10 17:48 4068

Noah Launches "Play The Full Game" Campaign with Singaporean Football Legend Fandi Ahmad as Brand Ambassador

SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- Noah, the telehealth platform tailored for men and created by Ordinary Folk, is pleased to announce the launch of its "Play The Full Game" campaign and the appointment ofFandi Ahmad as Noah's brand ambassador. The campaign aims to empower men to have the co...

2023-11-09 14:31 3346

West Pharmaceutical Services Appoints Nilesh Shah as Vice President and General Manager of Emerging Markets

SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, today announced it has appointed Nilesh Shah to serve as Vice President and General Manager of Emerging Mark...

2023-11-09 12:58 11137

DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells

Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function...

2023-11-09 08:15 3045

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...

2023-11-09 08:10 6417

Telix to Present at Jefferies London Healthcare Conference 2023

MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023. The presentation will take place o...

2023-11-09 04:51 2797

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology

TAIPEI, Nov. 8, 2023 /PRNewswire/ --  * AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients. * Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Acc...

2023-11-08 23:23 2649

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...

2023-11-08 13:00 3065
1 ... 92939495969798 ... 184